Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley L. Campbell Sells 7,500 Shares

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $11.46, for a total value of $85,950.00. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $10,161,054.84. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Amicus Therapeutics Trading Down 1.2 %

Shares of FOLD stock opened at $11.33 on Tuesday. The business’s 50 day moving average is $11.15 and its two-hundred day moving average is $10.59. The company has a quick ratio of 2.26, a current ratio of 2.75 and a debt-to-equity ratio of 2.93. Amicus Therapeutics, Inc. has a 12 month low of $9.02 and a 12 month high of $14.57. The company has a market cap of $3.36 billion, a PE ratio of -29.05 and a beta of 0.68.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05). Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The firm had revenue of $126.67 million during the quarter, compared to analyst estimates of $121.21 million. During the same quarter in the previous year, the business earned ($0.15) EPS. The business’s revenue was up 34.0% on a year-over-year basis. Equities analysts predict that Amicus Therapeutics, Inc. will post -0.06 EPS for the current year.

Hedge Funds Weigh In On Amicus Therapeutics

Several large investors have recently made changes to their positions in FOLD. Assenagon Asset Management S.A. bought a new position in Amicus Therapeutics in the 2nd quarter worth approximately $8,386,000. M&G Plc increased its position in Amicus Therapeutics by 12.4% during the second quarter. M&G Plc now owns 748,451 shares of the biopharmaceutical company’s stock worth $7,485,000 after acquiring an additional 82,728 shares during the period. Edgestream Partners L.P. raised its stake in Amicus Therapeutics by 1,290.4% during the 1st quarter. Edgestream Partners L.P. now owns 270,164 shares of the biopharmaceutical company’s stock valued at $3,183,000 after purchasing an additional 250,734 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its holdings in Amicus Therapeutics by 7.8% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 100,538 shares of the biopharmaceutical company’s stock valued at $1,183,000 after purchasing an additional 7,304 shares during the period. Finally, Fiera Capital Corp boosted its holdings in Amicus Therapeutics by 1.1% in the 2nd quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock valued at $52,382,000 after purchasing an additional 58,113 shares during the period.

Analysts Set New Price Targets

FOLD has been the topic of a number of research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 price objective on shares of Amicus Therapeutics in a research report on Friday, September 20th. Bank of America lifted their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, October 17th. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, October 31st. Morgan Stanley reduced their price objective on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research report on Friday, August 9th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, Amicus Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $17.13.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.